Samsung Bioepis

Overview
News
Biosimilars?
Product stageSegments
Early
?
Pure Play Biosimilars Developers
?

Samsung Bioepis is a biopharmaceutical company focused on developing and commercializing biosimilars and novel biologics. The company, headquartered in Incheon, South Korea, was established in 2012 as a joint venture between Samsung Biologics and Biogen. In April 2022, Samsung Biologics completed the full acquisition of Samsung Bioepis for USD 2.3 billion, making it a wholly owned subsidiary. Samsung Bioepis has built a robust portfolio of biosimilars across various therapeutic areas including immunology, oncology, ophthalmology, hematology, and endocrinology. The company's product offerings include biosimilars for treatments such as Remicade (infliximab), Humira (adalimumab), and Soliris (eculizumab). In addition to biosimilars, Samsung Bioepis has expanded into the development of novel biologics, with its lead candidate SB26 (TAK-671) entering clinical trials in 2018. The company utilizes a development platform aimed at addressing cost overruns and time delays in biologics development. Samsung Bioepis has received regulatory approvals for its products in multiple markets including the US, European Union, and South Korea.

Key customers and partnerships

Samsung Bioepis has established several strategic partnerships to enhance its market presence and product development capabilities. In February 2024, the company partnered with Samil Pharmaceutical to bring its aflibercept biosimilar, SB15, to the Korean market. This partnership followed a previous agreement in June 2022 for marketing Amelivu, a ranibizumab biosimilar. Samsung Bioepis collaborates with Sandoz for the commercialization of its ustekinumab biosimilar, Pyzchiva, in Europe, the US, Canada, the European Economic Area, Switzerland, and the UK. The company has also secured a contract with the US Department of Veterans Affairs to supply its Humira biosimilar, Hadlima, to VA hospitals for a five-year period starting February 2024. In the rare disease space, Samsung Bioepis launched Epysqli, its Soliris biosimilar, in South Korea in April 2024, offering it at a significantly reduced price compared to the reference product. The company has been selling Epysqli in European countries such as Germany, France, and Italy since 2023.


Sources

Disclaimer: This company profile has been generated using data obtained through automated web searches and advanced generative AI technology. While we strive to ensure the accuracy and reliability of our sources, auto-generated information could be outdated or inaccurate and should be verified independently.
HQ location:
107, Cheomdan-daero, Yeonsu-gu, Incheon Incheon KOR
Founded year:
2012
Employees:
501-1,000
IPO status:
Private
Total funding:
USD 667.5 mn
Last Funding:
USD 667.5 mn (Series Unknown; Jun 2018)
Last valuation:
USD 5.1 bn (Jun 2018)
Key competitors
Filter by the segments to which the disruptor belongs
All Segmentsexpand
 
Loading...
Loading...
Loading...
Loading...
Product Overview
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Product Metrics
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Company profile
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
-
Loading...
Loading...
Loading...
Loading...
Funding data are powered by Crunchbase
arrow
menuarrow
Click here to learn more
Get a demo

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.